GrowthNCT02410057
Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula
A study testing Protein-reduced α-lactalbumin formula, Protein-reduced whey formula and Standard infant formula in people with Growth and Infection, run by Skane University Hospital at 1 site in Sweden.
Trial summary
Formula composition is developed to resemble breast milk as close as possible, but there are still considerable differences between formula and breast milk composition, probably resulting in higher risk of overweight in childhood and higher incidence of infections in formula-fed infants. Read more about this study
- Who is it for?
- Ages 4 to 8 weeksHealthy volunteers can take part
- What is being tested?
- Protein-reduced α-lactalbumin formula, Protein-reduced whey formula and Standard infant formula
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 328 participants
- Where
- 1 siteSweden
- Study dates
- Nov 2014to Dec 2024
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 4 to 8 weeks
- All sexes
- Healthy volunteers accepted
- Child
Who may be able to join
- Healthy infants
- Born vaginally (no caecerian section)
- 37+0 until 42+0
- Birth weight ± 2 SD of internationally approved growth charts
- No severe neonatal problems
- No feeding problems
- No evidence of systemic disease
Who cannot join
- Partial breast feeding at 8 weeks
- Breast feeding in the formula Group
- Formula feeding in the breast fed Group
- Caecerian section
- Treatment with antibiotics during the first 8 weeks
Trial locations and contacts
1 site in 1 country.
About this study
Official title: ALFoNS - Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula Compared to Breastfed Infants
Formula composition is developed to resemble breast milk as close as possible, but there are still considerable differences between formula and breast milk composition, probably resulting in higher risk of overweight in childhood and higher incidence of infections in formula-fed infants. Protein levels are still higher and constituents such as alpha-lactalbumin lower in formula than in breast milk. By adding more alpha-lactalbumin to formula, rich in tryptophan, the resulting amino acid composition will allow further reduction of protein in formula. The investigators intend to include 320 infants, where 80 will be exclusively breastfed and the remainder assigned in a double blind, controlled, randomized manner to one of three formula groups; two experimental, protein reduced formula with two different levels of alpha-lactalbumin and one group given standard infant formula. The intervention period is from 4-8 weeks until 6 months of age. The infants will be followed by growth parameters, blood-, urine- and fecal biomarkers and health parameters until 5 years of age. The experimental formula will possibly result in growth, metabolism and gut microbiota as well as health parameters more similar to those of breastfed infants
Read the detailed description
Background: Breast milk is the best source of nutrition for the rapidly growing infant since it contains all the necessary nutrients in the right proportions. If the mother cannot breast-feed, chooses not to breast-feed or has to stop early, an adapted formula is from a nutritional perspective the only alternative during the first four to six months of age and also the best alternative throughout the rest of the first year of life together with suitable complementary foods. Formula composition has through the years developed to resemble as close as possible the composition of breast milk resulting in physiological effects in the infant to more resemble that of the breast-fed infant. However, there are still considerable differences between the dietary intake of the breast-fed infant and its metabolism compared to infants who are fed formula. Furthermore, research suggests that breast-fed infants have a lower risk of overweight and obesity in childhood and adolescence, lower risk of acute otitis media (AOM), upper airway- and gastrointestinal infections, and possibly a lower risk of high blood pressure and diabetes type 2 as adults which probably depend on different protein composition and concentration in formula and breastmilk. The optimal protein level of formula is still under debate. The investigators know that the protein concentration of formula is unnecessarily high, but until now it has been difficult to reduce it further due to the potential risk of shortage of some of the essential amino acids, i.e. those amino acids that have to be delivered from the diet.
The concentration of alpha-lactalbumin, the predominating whey protein in breast milk, is still low in formula. The composition of the protein in breast milk and formula thus differs considerably and consequently also the amino acid pattern in serum between infants who are breast-, or formula-fed. Alpha-lactalbumin has many potential positive effects which may explain some of the differences between breast-fed and formula-fed infants and when added to formula makes it more similar to the composition of breast milk. Alpha-lactalbumin contains a higher concentration of cysteine, a precursor of taurine, which is important for neurodevelopment. However, it is foremost the concentration of tryptophan that is higher in alpha-lactalbumin, an amino acid which otherwise is a limiting factor when lowering the protein level in formula. Tryptophan is a precursor of serotonin, a neurotransmitter important for stress management, cognition under stress and sleep latency.
Recently, new whey protein sources which contain higher concentrations of alpha-lactalbumin have become available. Studies show that protein is still too high in formula resulting in higher concentrations of urea nitrogen and most amino acids in infants who are fed formula compared to those who are breast-fed, which indicates that formula-fed infants still have excessive protein intake. Thus, there should be no problem in further reducing the protein level of formula during the first 6 months of life by increasing the proportion of alpha-lactalbumin. In this way the investigators might achieve a growth pattern and a metabolism more similar to that of the breast-fed infant. Acid whey protein is already in use today by some producers to obtain whey to casein ratio more similar to that of breast milk and to increase the concentration of tryptophan, which is an alternative, in increasing the proportion of alpha-lactalbumin. In this study the investigators intend to study both possibilities.
Alpha-lactalbumin has been suggested to influence the gut bacterial flora with a positive antimicrobial effect and improved immune function of the infant. Hypothetically, an increased intake of alpha-lactalbumin may result in fewer infections in formula-fed infants and thus decrease the differences in infection prevalence between formula- and breast-fed infants. Alpha-lactalbumin also seems to influence the uptake of minerals, such as iron, which could be important for iron status of the infant. Thus, iron status may improve in formula-fed infants when alpha-lactalbumin is added to formula, which has previously been shown by us and others.
With metabolomics, chemical processes involving metabolites, small molecule substrates, intermediates and products of metabolism are studied. Specifically, metabolomics is identifies a unique chemical fingerprints that specific cellular processes leave behind". Differences in metabolomics between the different groups will be studied Objectives: The purpose of the present study is to evaluate the effect of feeding infants a protein-reduced infant formula with high or low levels of alpha-lactalbumin on growth, metabolic markers and gut microbiota composition.
Methods: Healthy infants with normal growth parameters will be included. If the infant is fully formula-fed at 4-8 weeks of age, he or she will be randomized in a double blinded controlled manner to one of the three formula groups and receive the assigned infant formula until 6 month of age. The investigators will also include exclusively breast fed infants, whose mothers intend to breast-feed for at least 6 months, in a breastfed group.
From inclusion through the 12th month of age dietary intake, the incidence and duration of illness, stool consistency, fever, gastrointestinal problems, respiratory problems, and during the first 6 months also sleep- and crying time, will be recorded by the parents. Hospitalization and unscheduled doctor's visits will also be recorded by parents as well as medication (type, duration) and any adverse effects. Growth and well-being will be followed. Blood samples will be taken for analyses of protein metabolism and metabolomics and fecal microbiota will be analyzed as well as metabolites in urine.
Outcomes: Through this study the investigators should be able to clarify if feeding infants a protein-reduced formula with addition of alpha-lactalbumin or acid whey protein will affect growth, metabolic markers, gut microbiota composition and health parameters to approach those of breast-fed infants with possibly lower risk of overweight in childhood and lower incidences of infections in formula-fed infants.
- Being tested
- Protein-reduced α-lactalbumin formula, Protein-reduced whey formula, Standard infant formula
- Keywords
- growth, formula, protein, alpha-lactalbumin, amino acids, metabolomics, microbiota
- Medical subject headings
- Infections
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Protein-reduced α-lactalbumin formulaDietary supplement
Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula
Protein-reduced whey formulaDietary supplement
Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
Standard infant formulaDietary supplement
Standard infant formula
| Study group | Role | What they receive |
|---|---|---|
| Standard infant formula | Active comparator | Standard infant formula Receives: Dietary Supplement: Standard infant formula |
| Protein-reduced whey formula | Experimental | Protein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula Receives: Dietary Supplement: Protein-reduced whey formula |
| Protein-reduced α-lactalbumin formula | Experimental | Protein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula Receives: Dietary Supplement: Protein-reduced α-lactalbumin formula |
| Breast-feeding | No intervention | Exclusive breast-feeding |
What is being measured
The primary outcome is the main question the study is designed to answer.
Growth
body composition
Measured: 5 years
Secondary outcomes (3)
Gut microbiota
Feacal tests
Measured: 5 years
Infection frequency
Reported infections
Measured: 1 year
sleep
sleep latency
Measured: 2-6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Apr 2015 (estimated)
- Study startNov 2014
- Primary completionApr 2020
- Study completionDec 2024 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (6)Papers the sponsor has linked to this study.
- Other trials for GrowthStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 328 participants (actual)
Sponsor and investigators
- Lead sponsor
- Skane University Hospital
- Sponsor type
- University, hospital or other
- Collaborators
- University of California, Davis, Umeå University, Arla Foods
- Responsible party
- Principal investigator, Pia Karlsland Åkeson, Lund University
- Investigators
- Pia M Karlsland Åkeson, MD, PhD, Principal investigator, Lund University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02410057
- Sponsor's protocol ID
- SkaneUH
- Status last verified
- Aug 2022
- First submitted
- 20 Mar 2015
- Last updated
- 18 Aug 2022
- Results posted
- No
- Data monitoring committee
- No
- Individual data sharing
- No
Publications
Lonnerdal B, Lien EL. Nutritional and physiologic significance of alpha-lactalbumin in infants. Nutr Rev. 2003 Sep;61(9):295-305. doi: 10.1301/nr.2003.sept.295-305.
PubMed 14552064ESPGHAN Committee on Nutrition; Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, Michaelsen KF, Mihatsch W, Moreno LA, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J. Breast-feeding: A commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):112-25. doi: 10.1097/MPG.0b013e31819f1e05.
PubMed 19502997Karlsland Akeson PM, Axelsson IE, Raiha NC. Protein and amino acid metabolism in three- to twelve-month-old infants fed human milk or formulas with varying protein concentrations. J Pediatr Gastroenterol Nutr. 1998 Mar;26(3):297-304. doi: 10.1097/00005176-199803000-00011.
PubMed 9523865Axelsson IE, Jakobsson I, Raiha NC. Formula with reduced protein content: effects on growth and protein metabolism during weaning. Pediatr Res. 1988 Sep;24(3):297-301. doi: 10.1203/00006450-198809000-00004.
PubMed 3062558He X, Tinghall Nilsson U, Mishchuk DO, Hernell O, Lonnerdal B, Hartvigsen ML, Jacobsen LN, Kvistgaard AS, Slupsky CM, Karlsland Akeson P. Impact of formula protein quantity and source on infant metabolism: serum, urine, and fecal metabolomes of a randomized controlled study. Am J Clin Nutr. 2025 Apr;121(4):853-864. doi: 10.1016/j.ajcnut.2025.02.002. Epub 2025 Feb 5.
PubMed 39921093Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
PubMed 33006765
Study at a glance
From the registry record, last updated by the sponsor on 18 Aug 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- ALFoNS - Growth and Metabolism in Infants Fed Protein-reduced, Alpha-lactalbumin Enriched Formula Compared to Breastfed Infants
- ClinicalTrials.gov ID
- NCT02410057
- Acronym / sponsor ID
- SkaneUH
- Keywords
- growth, formula, protein, alpha-lactalbumin, amino acids, metabolomics, microbiota
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 328 participants (actual)
- Lead sponsor
- Skane University HospitalUniversity, hospital or other
- Collaborators
- University of California, Davis, Umeå University, Arla Foods
- Study start
- Nov 2014
- Primary completion
- Apr 2020 (actual)
- Study completion
- Dec 2024 (estimated)
- First posted
- 7 Apr 2015 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Formula composition is developed to resemble breast milk as close as possible, but there are still considerable differences between formula and breast milk composition, probably resulting in higher risk of overweight in childhood and higher incidence of infections in formula-fed infants. Protein levels are still higher and constituents such as alpha-lactalbumin lower in formula than in breast milk. By adding more alpha-lactalbumin to formula, rich in tryptophan, the resulting amino acid composition will allow further reduction of protein in formula. The investigators intend to include 320 infants, where 80 will be exclusively breastfed and the remainder assigned in a double blind, controlled, randomized manner to one of three formula groups; two experimental, protein reduced formula with two different levels of alpha-lactalbumin and one group given standard infant formula. The intervention period is from 4-8 weeks until 6 months of age. The infants will be followed by growth parameters, blood-, urine- and fecal biomarkers and health parameters until 5 years of age. The experimental formula will possibly result in growth, metabolism and gut microbiota as well as health parameters more similar to those of breastfed infants
Detailed description
Background: Breast milk is the best source of nutrition for the rapidly growing infant since it contains all the necessary nutrients in the right proportions. If the mother cannot breast-feed, chooses not to breast-feed or has to stop early, an adapted formula is from a nutritional perspective the only alternative during the first four to six months of age and also the best alternative throughout the rest of the first year of life together with suitable complementary foods. Formula composition has through the years developed to resemble as close as possible the composition of breast milk resulting in physiological effects in the infant to more resemble that of the breast-fed infant. However, there are still considerable differences between the dietary intake of the breast-fed infant and its metabolism compared to infants who are fed formula. Furthermore, research suggests that breast-fed infants have a lower risk of overweight and obesity in childhood and adolescence, lower risk of acute otitis media (AOM), upper airway- and gastrointestinal infections, and possibly a lower risk of high blood pressure and diabetes type 2 as adults which probably depend on different protein composition and concentration in formula and breastmilk. The optimal protein level of formula is still under debate. The investigators know that the protein concentration of formula is unnecessarily high, but until now it has been difficult to reduce it further due to the potential risk of shortage of some of the essential amino acids, i.e. those amino acids that have to be delivered from the diet.
The concentration of alpha-lactalbumin, the predominating whey protein in breast milk, is still low in formula. The composition of the protein in breast milk and formula thus differs considerably and consequently also the amino acid pattern in serum between infants who are breast-, or formula-fed. Alpha-lactalbumin has many potential positive effects which may explain some of the differences between breast-fed and formula-fed infants and when added to formula makes it more similar to the composition of breast milk. Alpha-lactalbumin contains a higher concentration of cysteine, a precursor of taurine, which is important for neurodevelopment. However, it is foremost the concentration of tryptophan that is higher in alpha-lactalbumin, an amino acid which otherwise is a limiting factor when lowering the protein level in formula. Tryptophan is a precursor of serotonin, a neurotransmitter important for stress management, cognition under stress and sleep latency.
Recently, new whey protein sources which contain higher concentrations of alpha-lactalbumin have become available. Studies show that protein is still too high in formula resulting in higher concentrations of urea nitrogen and most amino acids in infants who are fed formula compared to those who are breast-fed, which indicates that formula-fed infants still have excessive protein intake. Thus, there should be no problem in further reducing the protein level of formula during the first 6 months of life by increasing the proportion of alpha-lactalbumin. In this way the investigators might achieve a growth pattern and a metabolism more similar to that of the breast-fed infant. Acid whey protein is already in use today by some producers to obtain whey to casein ratio more similar to that of breast milk and to increase the concentration of tryptophan, which is an alternative, in increasing the proportion of alpha-lactalbumin. In this study the investigators intend to study both possibilities.
Alpha-lactalbumin has been suggested to influence the gut bacterial flora with a positive antimicrobial effect and improved immune function of the infant. Hypothetically, an increased intake of alpha-lactalbumin may result in fewer infections in formula-fed infants and thus decrease the differences in infection prevalence between formula- and breast-fed infants. Alpha-lactalbumin also seems to influence the uptake of minerals, such as iron, which could be important for iron status of the infant. Thus, iron status may improve in formula-fed infants when alpha-lactalbumin is added to formula, which has previously been shown by us and others.
With metabolomics, chemical processes involving metabolites, small molecule substrates, intermediates and products of metabolism are studied. Specifically, metabolomics is identifies a unique chemical fingerprints that specific cellular processes leave behind". Differences in metabolomics between the different groups will be studied Objectives: The purpose of the present study is to evaluate the effect of feeding infants a protein-reduced infant formula with high or low levels of alpha-lactalbumin on growth, metabolic markers and gut microbiota composition.
Methods: Healthy infants with normal growth parameters will be included. If the infant is fully formula-fed at 4-8 weeks of age, he or she will be randomized in a double blinded controlled manner to one of the three formula groups and receive the assigned infant formula until 6 month of age. The investigators will also include exclusively breast fed infants, whose mothers intend to breast-feed for at least 6 months, in a breastfed group.
From inclusion through the 12th month of age dietary intake, the incidence and duration of illness, stool consistency, fever, gastrointestinal problems, respiratory problems, and during the first 6 months also sleep- and crying time, will be recorded by the parents. Hospitalization and unscheduled doctor's visits will also be recorded by parents as well as medication (type, duration) and any adverse effects. Growth and well-being will be followed. Blood samples will be taken for analyses of protein metabolism and metabolomics and fecal microbiota will be analyzed as well as metabolites in urine.
Outcomes: Through this study the investigators should be able to clarify if feeding infants a protein-reduced formula with addition of alpha-lactalbumin or acid whey protein will affect growth, metabolic markers, gut microbiota composition and health parameters to approach those of breast-fed infants with possibly lower risk of overweight in childhood and lower incidences of infections in formula-fed infants.
Study design
- Primary purpose
- Basic science
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 4
| Arm | Type | Receives |
|---|---|---|
| Standard infant formula | Active comparator | Dietary Supplement: Standard infant formulaStandard infant formula |
| Protein-reduced whey formula | Experimental | Dietary Supplement: Protein-reduced whey formulaProtein-reduced whey formula with higher level of α-lactalbumin than in standard infant formula |
| Protein-reduced α-lactalbumin formula | Experimental | Dietary Supplement: Protein-reduced α-lactalbumin formulaProtein-reduced formula with level of α-lactalbumin more similar to breast milk and higher than in experimental whey formula and in standard infant formula |
| Breast-feeding | No intervention | –Exclusive breast-feeding |
Who may qualify
- Ages
- 4 to 8 weeks
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child
Key inclusion criteria (7 listed)
- Healthy infants
- Born vaginally (no caecerian section)
- 37+0 until 42+0
- Birth weight ± 2 SD of internationally approved growth charts
- No severe neonatal problems
Key exclusion criteria (5 listed)
- Partial breast feeding at 8 weeks
- Breast feeding in the formula Group
- Formula feeding in the breast fed Group
- Caecerian section
- Treatment with antibiotics during the first 8 weeks
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Protein-reduced α-lactalbumin formulaProtein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula and in standard infant formula | Dietary supplement | Protein-reduced α-lactalbumin formula |
| Protein-reduced whey formulaProtein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula | Dietary supplement | Protein-reduced whey formula |
| Standard infant formulaStandard infant formula | Dietary supplement | Standard infant formula |
Primary outcome
Growth
Time frame: 5 years
body composition
3 secondary outcomes
Gut microbiota
Time frame: 5 years
Infection frequency
Time frame: 1 year
sleep
Time frame: 2-6 months
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Aug 2022.
- Background: PubMed 14552064Lonnerdal B, Lien EL. Nutritional and physiologic significance of alpha-lactalbumin in infants. Nutr Rev. 2003 Sep;61(9):295-305. doi: 10.1301/nr.2003.sept.295-305.
- Background: PubMed 19502997ESPGHAN Committee on Nutrition; Agostoni C, Braegger C, Decsi T, Kolacek S, Koletzko B, Michaelsen KF, Mihatsch W, Moreno LA, Puntis J, Shamir R, Szajewska H, Turck D, van Goudoever J. Breast-feeding: A commentary by the ESPGHAN Committee on Nutrition. J Pediatr Gastroenterol Nutr. 2009 Jul;49(1):112-25. doi: 10.1097/MPG.0b013e31819f1e05.
- Background: PubMed 9523865Karlsland Akeson PM, Axelsson IE, Raiha NC. Protein and amino acid metabolism in three- to twelve-month-old infants fed human milk or formulas with varying protein concentrations. J Pediatr Gastroenterol Nutr. 1998 Mar;26(3):297-304. doi: 10.1097/00005176-199803000-00011.
- Background: PubMed 3062558Axelsson IE, Jakobsson I, Raiha NC. Formula with reduced protein content: effects on growth and protein metabolism during weaning. Pediatr Res. 1988 Sep;24(3):297-301. doi: 10.1203/00006450-198809000-00004.
- Derived from this study: PubMed 39921093He X, Tinghall Nilsson U, Mishchuk DO, Hernell O, Lonnerdal B, Hartvigsen ML, Jacobsen LN, Kvistgaard AS, Slupsky CM, Karlsland Akeson P. Impact of formula protein quantity and source on infant metabolism: serum, urine, and fecal metabolomes of a randomized controlled study. Am J Clin Nutr. 2025 Apr;121(4):853-864. doi: 10.1016/j.ajcnut.2025.02.002. Epub 2025 Feb 5.
- Derived from this study: PubMed 33006765Amari S, Shahrook S, Namba F, Ota E, Mori R. Branched-chain amino acid supplementation for improving growth and development in term and preterm neonates. Cochrane Database Syst Rev. 2020 Oct 2;10(10):CD012273. doi: 10.1002/14651858.CD012273.pub2.
- Individual participant dataSharing planned: No
Related trials for Growth
Recruiting
Short-Term Reduced Dietary Protein in ER+/HER2- Breast Cancer Patients During Neoadjuvant Chemotherapy
Breast Cancer, Hormone Receptor Positive / HER2-negative Breast Cancer
RecruitingPhase 3
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
RecruitingPhase 2
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
Breast Neoplasms, Breast Cancer
RecruitingPhase 1/2
A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
EGFR-Mutant Non-Small Cell Lung Cancer
Active, not recruitingPhase 2
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy
Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Pia M Karlsland Åkeson, MD, PhD principal investigator
Lund University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Protein-reduced α-lactalbumin formula, Protein-reduced whey formula and Standard infant formula in people with Growth and Infection, run by Skane University Hospital at 1 site in Sweden.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 5 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 18 Aug 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Sweden. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Growth (time frame: 5 years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02410057, which also lists 6 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Aug 2022.